聚糖
树突状细胞
交叉展示
免疫系统
CD8型
免疫学
抗原呈递
受体
淋巴系统
癌症免疫疗法
生物
免疫疗法
细胞生物学
T细胞
糖蛋白
分子生物学
生物化学
作者
Sanne Duinkerken,R.J. Eveline Li,Floortje J. van Haften,Tanja D. de Gruijl,Fabrizio Chiodo,Sjoerd Schetters,Yvette van Kooyk
标识
DOI:10.1016/j.cbpa.2019.10.001
摘要
Dendritic cell (DC)–targeting vaccines show great promise in increasing antitumor immunity. Glycan-engineered vaccines facilitate both DC targeting and increased uptake by DCs for processing and presentation to CD4+ and CD8+ T cells to induce tumor-specific T-cell responses. However, the complexity of various DC subsets in skin tissues, expressing different glycan-binding receptors that can mediate vaccine uptake or drainage of vaccines via lymphatics directly to the lymph node–resident DCs, complicates the success of vaccines. Moreover, the influx of inflammatory immune cells to the site of vaccination, such as monocytes that differentiate to DCs and coexpress glycan-binding receptors, may contribute to the strength of DC-targeting glycovaccines for future clinical use.
科研通智能强力驱动
Strongly Powered by AbleSci AI